NCT00426972 is a Phase 3 clinical trial of estradiol (Zesteem) in Burn, sponsored by Renovo.

Who is sponsoring NCT00426972?

NCT00426972 is sponsored by Renovo.

What drugs are being tested in NCT00426972?

Interventions in NCT00426972: estradiol (Zesteem).

What condition does NCT00426972 study?

NCT00426972 studies Burn, Trauma, Varicose Ulcer.

Is NCT00426972 still recruiting?

NCT00426972 is currently completed. Last updated 27 August 2009.

Last reviewed 2009-08-27 · How we verify

NCT00426972

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Double Blind, Placebo Controlled Trial to Investigate the Efficacy of Zesteem (Estradiol) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites.

Completed Phase 3 Last updated 27 August 2009

What this trial tests

Phase 3 trial testing estradiol (Zesteem) in Burn in 148 participants. Completed in 1 October 2008.

Timeline

1 January 2007

Primary endpoint
1 July 2008

1 October 2008

Quick facts

Lead sponsor	Renovo
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	148
Start date	1 January 2007
Primary completion	1 July 2008
Estimated completion	1 October 2008
Sites	30 locations across Germany, Latvia, Russia, United Kingdom

Drugs / interventions tested

estradiol (Zesteem) — full drug profile →

Conditions studied

Burn — all drugs for Burn →
Trauma — all drugs for Trauma →
Varicose Ulcer — all drugs for Varicose Ulcer →

Sponsor

Renovo — full company profile →

Who can join

Adults 18 to 85, any sex, with Burn or Trauma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Complete wound closure of skin graft donor site.

Sponsor's own description

This trial will assess the effects of Zesteem (estradiol) on the healing of split thickness skin graft donor sites in patients aged 18-85 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Burn

Currently open trials in the same condition.

NCT07221903 — The Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA · recruiting
NCT06992895 — The Effect of Hologram Application on Pain, Anxiety, and Fear Levels in Children During Burn Dressing · NA · recruiting
NCT07453927 — Blue Light for Donor Site Healing in Burn Patients · NA · recruiting
NCT07025408 — Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00426972 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Renovo
Last refreshed: 27 August 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00426972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing